US equities
|
NVDA
$238.84
▲+2.09%
SPCX
$167.71
▲+5.50%
MU
$1,062.55
▼-1.15%
TSLA
$380.41
▲+2.65%
MSFT
$526.21
▲+1.68%
SNDK
$1,702.96
▼-0.99%
INTC
$116.82
▼-2.10%
META
$742.54
▲+1.99%
NVDA
$238.84
▲+2.09%
SPCX
$167.71
▲+5.50%
MU
$1,062.55
▼-1.15%
TSLA
$380.41
▲+2.65%
MSFT
$526.21
▲+1.68%
SNDK
$1,702.96
▼-0.99%
INTC
$116.82
▼-2.10%
META
$742.54
▲+1.99%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Jasper Therapeutics, Inc.
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
September 15, 2026
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 09, 2026
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 14, 2026
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 11, 2023
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 10, 2022
From
Jasper Therapeutics, Inc.
Via
GlobeNewswire
Tickers
JSPR
Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
September 24, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members
September 20, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes
September 08, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant
June 14, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting
June 01, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease
May 26, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
May 19, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation
May 06, 2021
From
Jasper Therapeutics, Inc.
Via
Business Wire
